Director Patricia S Andrews bought 35,400 shares of ONCY at $0.86; 8 other insiders also bought within 14 days—cluster pattern signals coordinated conviction.
Andrews Patricia S, a director at Oncolytics Biotech, purchased 35,400 shares at $0.86 on 2026-02-12, increasing her stake from 42,728 to 78,128 shares—an 82.8% increase in her holdings. Notably, this purchase is part of a cluster in which 8 other insiders also bought within the past 14 days, indicating coordinated accumulation at a price point 25.4% below the 52-week high. The current stock price of $1.06 sits modestly above the transaction price, with recent momentum showing modest positive returns over 30-day and 90-day periods. This multi-insider buy pattern is the key signal: when directors and executives across the organization simultaneously increase exposure at depressed valuations within a short window, it often reflects shared conviction about near-term catalysts or undervaluation relative to fundamentals.